The Week Ahead: Fed...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$3.85 -0.08 | -2.04%
06/04/12 - 10:57 AM ET
Company Cash Flow
| Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -3.49M | -5.77M | -19.31M | -27.09M |
| Operating Gains/Losses | 424.40K | -10.88K | -1.35M | -7.75M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -736.25K | -783.43K | -60.66K | 188.62K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 18.47K | -114.83K | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 157.08K | -331.72K | -328.72K | -437.61K |
| (Decrease) Increase In Other Current Liabilities | 468.59K | 81.74K | -644.98K | -254.09K |
| (Increase) Decrease In Other Working Capital | 0.00 | 74.91K | 144.64K | -255.96K |
| Other Non-Cash Items | -4.85M | -1.57M | 5.21M | 6.36M |
| Net Cash From Continuing Operations | -7.66M | -7.70M | -15.28M | -27.58M |
| Net Cash From Discontinued Operations | 2.27M | -2.66K | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -5.39M | -7.70M | -15.28M | -27.58M |
| Sale of Property, Plant & Equipment | 0.00 | 63.00K | 79.38K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -9.67K | -5.41K | -40.24K | -684.11K |
| Acquisitions | -1.70M | 0.00 | 0.00 | 109.38K |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -2.00M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -175.38K | 487.59K | 739.13K | -2.57M |
| Issuance of Debt | 0.00 | 0.00 | 2.52M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 6.23M | 12.17M | 4.76M | 16.27M |
| Repayment of Long-Term Debt | 0.00 | -726.53K | -810.46K | -140.01K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 600.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 6.23M | 12.04M | 6.47M | 16.13M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 660.23K | 4.83M | -8.07M | -14.03M |
Portfolios with ARWR
- Portfolio NameUser Type
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
- Userpeaka22 Portfolio 1
- Userkevin sweeney Portfolio 1
- UserWORLD FREE
- Userkeyon communications
Latest ARWR Headlines from TheStreet
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
- Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript 08.12.10 | 06:08 pm
- Mediacom, Jones Soda: Midday Volume Plays 06.01.10 | 10:06 am
- Arrowhead Research, Verenium: Early Volume Plays 03.22.10 | 07:03 am
- Amicas, Limelight: Early Volume Plays 12.28.09 | 07:12 am
- Thursday's Small-Cap Winners & Losers 06.20.07 | 01:06 am
- Friday's ETF Winners & Losers 06.20.07 | 01:06 am
Press Releases for ARWR
- Arrowhead Presents Data On DPC System At TIDES 2012 - Business Wire 05.22.12 | 07:05 am
- Arrowhead Reports Fiscal 2012 Second Quarter Financial Results - Business Wire 05.08.12 | 04:05 pm
- Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides - Business Wire 04.11.12 | 07:04 am
- Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment - Business Wire 03.07.12 | 07:03 am
- Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics - Business Wire 03.05.12 | 07:03 am
- Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1) - Business Wire 02.29.12 | 07:02 am
- Arrowhead Reports Fiscal 2012 First Quarter Financial Results - Business Wire 02.09.12 | 04:02 pm
- Arrowhead To Report Fiscal 2012 First Quarter Financial Results - Business Wire 02.02.12 | 07:02 am
- Alnylam And Arrowhead Form Collaboration And Licensing Agreement - Business Wire 01.05.12 | 08:01 am
- Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial - Business Wire 01.04.12 | 07:01 am
Partner Headlines for ARWR
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
